Hematologic Oncology | Specialty

Dr. Ahmed on Axi-Cel Benefit in Patients With Primary Refractory LBCL

February 9th 2021

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

Dr. Horwitz on the Clinical Benefit of Omidubicel Transplant in Hematologic Malignancies

February 9th 2021

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

Fedratinib Approved in Europe for Newly Diagnosed and Previously Treated Myelofibrosis

February 9th 2021

February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.

Response to Prior Therapy Predicts Outcomes With Axi-Cel in Refractory Large B-Cell Lymphoma

February 9th 2021

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

Ruxolitinib Showcases Early Efficacy, Safety in Pediatric Chronic GVHD

February 9th 2021

February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.

Novel Combinations Move Into the Spotlight in Early Relapsed Multiple Myeloma

February 9th 2021

Shaji K. Kumar, MD, discusses novel combinations that are being introduced to the relapsed/refractory setting in multiple myeloma, the value of minimal residual disease, and the importance of understanding potential toxicity when utilizing newer agents in the space.

JSP191 With Low-Dose Irradiation and Fludarabine Shows Promise in MRD+ AML/MDS

February 9th 2021

February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

FDA Grants Breakthrough Therapy Designations to Asciminib for CML

February 9th 2021

February 9, 2021 - The FDA has granted breakthrough therapy designations to asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who received prior treatment with 2 or more TKIs, and for adult patients with Ph-positive CML in chronic phase whose tumors harbor the T315I mutation.

BTK Inhibitors for Relapsed MCL: Important Considerations

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

February 9th 2021

Narsoplimab Shows Impressive Responses, Survival Benefit in High-Risk HSCT-TMA

February 9th 2021

February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.

Liso-Cel Responses Not Impacted By Prior Anti-CD19 Therapy in Relapsed/Refractory Large B-Cell Lymphoma

February 8th 2021

February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8th 2021

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

February 8th 2021

Role of Dual Targeted Therapy in AML

February 8th 2021

Sequencing of FLT3 Inhibitors in AML

February 8th 2021

Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer

February 6th 2021

February 5, 2021 - Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 tend to have favorable outcomes, especially if they are diagnosed in complete remission and further out from their cell infusion.

Dr. Abramson on the FDA Approval of Liso-Cel in Refractory Large B-Cell Lymphoma

February 5th 2021

Jeremy S. Abramson, MD, discusses the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma.

FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma

February 5th 2021

February 5, 2021 - The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma

February 5th 2021

February 5, 2021 - The FDA has approved lisocabtagene maraleucel for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.